Sanofi is a large pharma headquartered in France. Over the past three years, Sanofi has been involved in 24 licensing and acquisition transactions, with a primary focus on Small Molecules (11 deals). The company currently has 50 active clinical trials, primarily in Immunology.
Deals (12mo)
2
Active Trials
50
Top Modality
Small Molecules
Focus Area
Immunology
Licensing, acquisition, and partnership transactions involving Sanofi in the past 12 months.
| Asset |
|---|
| Partner |
|---|
| Modality |
|---|
| Phase |
|---|
| Type |
|---|
| Date |
|---|
| rovadicitinib | Chia Tai Tianqing | Small Molecules | Unknown | license | Jul 1, 2026 |
| rovadicitinib | Chia Tai Tianqing (Sino Biopharm) | Small Molecules | Unknown | license | Jun 27, 2026 |
| Dynavax adjuvant and vaccine portfolio | Dynavax Technologies | Vaccines | Unknown | acquisition | Jun 15, 2026 |
| Blueprint Medicines portfolio | Blueprint Medicines | Small Molecules | Unknown | acquisition | May 15, 2026 |
| mRNA influenza vaccine program | MIT Anderson Lab | mRNA | Phase 1 | collaboration | May 14, 2026 |
| NanoDisc platform | Evoq Therapeutics | Other | Preclinical | license | May 2, 2026 |
| duvakitug | Teva | Antibodies | Phase 2 | collaboration | Apr 17, 2026 |
| AXPAXLI | Ocular Therapeutix | Other | Phase 3 | acquisition | Mar 31, 2026 |
| rovadicitinib | Sino Biopharm (Chia Tai Tianqing) | Small Molecules | Unknown | license | Mar 15, 2026 |
| rovadicitinib | Sino Biopharmaceutical | Small Molecules | Phase 2 | license | Mar 4, 2026 |
Showing 10 of 11 recent transactions. Upgrade to Pro for full deal history with financials.
Therapeutic areas and modalities where Sanofi is most active based on deal history and clinical trial data.
Key indicators of Sanofi's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
Sanofi has 50 active clinical trials across 6 development phases.
9
Unknown
6
Phase 4
2
Not Applicable
4
Phase 1
10
Phase 2
19
Phase 3
Use Solidus to benchmark upfront payments, milestones, and royalties for Immunology assets — powered by data from 3,500+ real biopharma transactions.
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Sanofi is a large pharma company based in France that has been actively engaged in licensing transactions across the biopharma landscape. With 24 deals over the past three years, Sanofi ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sanofi include Immunology (13 deals and trials), Autoimmune (7 deals and trials), Metabolic (7 deals and trials), and Oncology (5 deals and trials). In terms of modality, Sanofi has shown particular interest in small molecules, other, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sanofi and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Sanofi's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,600+ real biopharma licensing deals